All News

Article

Proposed Cancer Screening for Inflammatory Myositis Patients

Jack Cush, MD

Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.  Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this thorny practice issue. 

Robert B Chao, MD Tweet
doctorRBC
Good news for patients who require short interruptions in biologic therapy! Majority of axSpA patients (82%) who restarted ixekizumab after withdrawing, achieved low disease activity and 68% eventually had inactive disease. #Abs0427 @RheumNow #ACR22
Eric Dein Tweet
ericdeinmd
Ab0192: UPA vs ADA vs PBO on RAPID3 in SELECT-PsA (bio-naive, P3 trial) #ACR22 UPA>ADA from wk 16-56. UPA and ADA>>PBO Strongly associates with DAPSA or MDA/VLDA composite scores @RheumNow https://t.co/ABY12ar7RS
Olga Petryna Tweet
DrPetryna
#abst037 #acr22 @rheumnow REGISPONSER &  RESPONDIA study of 231 pts w/late- vs early-onset PsA: late-onset> often male , ⬆️structural damage, ⬆️ FASFI, ⬆️ UE arthritis. Sacroiliitis& enthesitis ⬇️ frequent in late-onset. No effect on quality of life, dis activity & Rx choice https://t.co/IPRc1r2sxZ
Catherine Sims, MD Tweet
DrCassySims
How do we decide which RA patients are best for #telehealth? Abstract #1291, Ignite session 🖥@DavidLeverenz et. al created a predictive model to answer this question 🖥Patient age, diagnosis, medications, and RAPID3 score impacted the model @RheumNow #ACR22 https://t.co/JztTbQ4zfZ
Patricia Harkins Tweet
DrTrishHarkins
RTX vs CYCLO for CTD ILD 🌟RECITAL trial🌟 🫁Best ⬆️ in lung fn seen in IIM + MCTD assoc ILD for both agents 🫁SSc-ILD- lung function stabilisation only (no ⬆️) 👉 In SSc RTX improved skin thickness (mRss 24wks) ⬇️ a/e RTX #ACR22 @RheumNow Abst#0003 #plenary https://t.co/XdaaSFfxSP
David Liew Tweet
drdavidliew
Question is: does early stage PNL protect vs vascular remodelling in GCA? What about TCZ? Salvarini group: 18 new GCA pts GUSTO Rx (TCZ +IVMPx3, no ongoing PNL) PET/CT: 0, 24, 52w inflamm controlled but aortic diltation plausible concerns reinforced! ABST0480 #ACR22 @RheumNow https://t.co/Wnw4oxaZn7
Janet Pope Tweet
Janetbirdope
RECITAL trial #CTD with #ILD RCT of #rituximab vs #cyclophosphamide showed value overall with each Rx. Only 6 months as then maybe you would retreat w rituximab? Not superior on lungs but in #scleroderma-skin improvement better w RTX. #ACRBest #ACR22 @RheumNow abst#3 Impt for Rx https://t.co/lX1YPsr5U6
Mike Putman Tweet
EBRheum
I implemented a Fast Track GCA clinic at my hospital (>60 encounters now!) I have have begun to think the main benefit is ACCESS Ultrasound is great and I do them, but I recommend starting one REGARDLESS of whether or not you do ultrasound #ACR22 @RheumNow #0463 https://t.co/4uuotmNnoi
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#ACR2022 Abstr#0003. Subgroup analysis from RECITAL RCT Rituximab vs Cyclophosphamide in CTD-ILD showed both therapies improved FVC in Myositis and MCTD but not Scleroderma. To interpret with caution (non-powered). Key message: To consider RTX as option for CTD-ILD @RheumNow https://t.co/NhJKXRdw7q
Olga Petryna Tweet
DrPetryna
#acr22 #abst0003 @RheumNow RECITAL: RTX vs CYC for CTD related ILD:comparable in MCTD, CYC better for myositis related ILD. Both stabilize but not improve FVC in SSc ILD. In SSc RTX but not CYC improved skin thickness by mRss at 24 wks. better safety of RTX vs CYC #acrbest https://t.co/6Hry5hy1SS
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×